During 2021, biomarker studies of post-stroke epilepsy and in relation to status epilepticus have been developing within the competitive projects of this line. In addition, this is helping to carry out the first serological database of patients with emergent epileptic seizures, which will help to further studies of biomarkers related to epileptogenesis or drug-resistant epilepsy. On the other hand, studies have also been conducted in the field of cognitive reserve and degeneration in patients with epilepsy. With regard to publications in 2021 (a total of 25 indexed publications), the group has positioned itself as a reference in epilepsy and women, post-stroke epilepsy and continued clinical research in status epilepticus and emergent seizures. In addition, it remains consolidated as one of the groups with the highest recruitment of clinical trials in epilepsy, which translates into several publications.

Group Leader
Estevo Santamarina Pérez

Principal Investigator (PI)
Manuel Toledo, Estevo Santamarina

Researchers
Laura Abraira, Elena Fonseca, Manuel Quintana

PhD Students
Ariadna Gifreu, Daniel Campos

Nursing and Technical Staff
Javier Sánchez

27

PUBLICATIONS

106

IMPACT FACTOR

3.94

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Liguori C, Toledo M, Kothare S
Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: A literature review.
Sleep Med Rev. 2021 Dec;60:101559
DOI: 10.1016/j.smrv.2021.101559
IF: 11.609

Ferreira-Atuesta C, Döhler N, Erdélyi-Canavese B, Felbecker A, Siebel P, Scherrer N, Bicciato G, Schweizer J, Sinka L, Imbach LL, Katan M, Abraira L, Santamarina E, Álvarez-Sabín J, Winklehner M, von Oertzen TJ, Wagner JN, Gigli GL, Serafini A, Janes F, Merlino G, Valente M, Gregoraci G, Conrad J, Evers S, Lochner P, Roell F, Brigo F, Bentes C, Peralta AR, Melo TPE, Keezer MR, Duncan JS, Sander JW, Tettenborn B, Koepp MJ, Galovic M.
Seizures after ischemic stroke: a matched multicenter study
Ann Neurol. 2021 Nov;90(5):808-820
DOI: 10.1002/ana.26212
IF: 10.422

Cano A, Fonseca E, Ettcheto M, Sánchez-López E, de Rojas I, Alonso-Lana S, Morató X, Souto EB, Toledo M, Boada M, Marquié M, Ruíz A
Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways.
Pharmaceuticals (Basel). 2021 Oct 18;14(10):1057.
DOI: 10.3390/ph14101057
IF: 5.863

Lallana S, Fonseca E, Restrepo JL, Quintana M, Seijo-Raposo I, Abraira L, Santamarina E, Álvarez-Sabín J, Toledo M.
Medium-term effects of COVID-19 pandemic on epilepsy: A follow-up study
Acta Neurol Scand. 2021 Jul;144(1):99-108.
DOI: doi: 10.1111/ane.13439
IF: 3.209

Santamarina E, Parejo-Carbonell B, Abraira L, Gutiérrez-Viedma A, Fonseca E, Seijo I, Abarrategui B, Salas-Puig X, Quintana M, Toledo M, García-Morales I.
Status epilepticus without impairment of consciousness: Long-term outcomes according to duration
Epilepsy Behav. 2021 Jul;120:108007.
DOI: 10.1016/j.yebeh.2021.108007
IF: 2.937

Uso de marcadores en la detección de crisis epilépticas de mal pronóstico
Principal Investigator: Estevo Santamarina
Agency: Instituto de Salud Carlos III
Funding: 73,810 €
Period: 2020-2022

Study of the mechanisms within the acute phase of stroke that enhance the development of epilepsy
Principal Investigator: José Álvarez Sabín. Collaborating Researchers (VHIR): Estevo Santamarina, Laura Abraira, Manuel Quintana
Agency: Fundació Marató TV3
Funding: 243,391.07 €
Period: 2018-2021

A European non-interventional study to understand the criteria used and the time required for the clinical diagnosis in participants with refractory epilepsies associated with developmental delay.
Principal Investigator: Manuel Toledo
Agency: Zogenix International Limited
Funding: 4,254.58 €
Period: 2020-2021

Antiepilépticos y control de crisis nocturnas: eficacia, tolerabilidad y efectos cognitivos
Principal Investigator: Manuel Toledo
Agency: Eisai Farmacéutica, SA
Funding: 61,410 €
Period: 2020-2022

Neurosciences

Research Areas